Vanguard Group Inc. Has $194.86 Million Holdings in Omnicell, Inc. $OMCL

Key Points

• Vanguard Group Inc. increased its stake in Omnicell by 0.2%, owning 11.90% of the company, worth approximately $194.86 million after acquiring an additional 11,694 shares.
• Omnicell has received mixed analyst ratings, with a consensus rating of "Moderate Buy" and a price target of $46.71, despite Benchmark lowering its target from $62.00 to $40.00.
• For Q2, Omnicell reported $290.56 million in revenue, exceeding analyst estimates, and announced earnings guidance for FY 2025 between $1.400-$1.650 EPS.

Vanguard Group Inc. grew its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 0.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,573,859 shares of the company's stock after buying an additional 11,694 shares during the period. Vanguard Group Inc. owned approximately 11.90% of Omnicell worth $194,862,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in OMCL. New Age Alpha Advisors LLC bought a new position in shares of Omnicell during the 1st quarter valued at about $233,000. Arkadios Wealth Advisors lifted its holdings in shares of Omnicell by 7.5% during the 1st quarter. Arkadios Wealth Advisors now owns 46,705 shares of the company's stock valued at $1,633,000 after purchasing an additional 3,251 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Omnicell by 316.1% during the 1st quarter. XTX Topco Ltd now owns 30,295 shares of the company's stock valued at $1,059,000 after purchasing an additional 23,015 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Omnicell in the 1st quarter valued at approximately $901,000. Finally, Pacer Advisors Inc. bought a new stake in Omnicell in the 1st quarter valued at approximately $10,542,000. Institutional investors own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on OMCL. Bank of America boosted their target price on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Wells Fargo & Company boosted their target price on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Piper Sandler cut their target price on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Benchmark cut their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Stock Performance

NASDAQ OMCL traded up $1.73 on Friday, reaching $33.62. The stock had a trading volume of 863,923 shares, compared to its average volume of 619,977. The firm has a fifty day moving average of $29.62 and a two-hundred day moving average of $31.92. The company has a market cap of $1.54 billion, a P/E ratio of 67.24, a price-to-earnings-growth ratio of 9.31 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The firm had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. During the same period in the prior year, the company posted $0.51 EPS. The company's revenue was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.